FORXIGA® (dapagliflozin)

FORXIGA® (dapagliflozin) is a highly selective SGLT2 inhibitor for type 2 diabetes mellitus, with 4-year safety and efficacy data, that removes glucose and its associated calories via the kidney.1

Our Pooled Real-World Evidence

Visibly improved outcomes for every day patients, in the real world.15

Across the UK, patients receiving FORXIGA® (dapagliflozin) experienced reductions in both HbA1c and weight at year 1*15

Pooled real-world evidence data at 1 year for patients treated with FORXIGA®
Pooled real-world evidence data at 1 year for patients treated with FORXIGA®

Adapted from Wilding J et al. 2017: Appendix A.

70.2% of patients achieved reductions in HbA1c and bodyweight15

*FORXIGA® (dapagliflozin) is not indicated for weight loss.1

All ‘on label’ patients within measures.15

The chart reflects the data from 943 pateints for whom a reading was taken at the time-points specified, and not the total number of patients who entered the study.15

Results from Real-World Evidence studies may not necessarily relate to the effect of the intervention/treatment alone. 

Results should be interpreted in the context of RCT findings

Pooled clinical trial data

Pooled clinical trial data show that patients receiving FORXIGA® (dapagliflozin) experienced reductions in both HbA1c and weight at 6 months18

Pooled real-world evidence data at 6 months for patients treated with FORXIGA®
Pooled real-world evidence data at 6 months for patients treated with FORXIGA®

Adapted from Hardy E et al. 2012

65.7% of patients achieved reductions in both HbA1c and bodyweight vs 31.9% for placebo18

*FORXIGA® (dapagliflozin)is not indicated for weight loss. Weight change was a secondary endpoint in clinical trials1

The distribution of change from baseline to Week 24 in HbA1c and body weight in individual patients pooled from five of the core FORXIGA® (dapagliflozin) phase 3 randomised placebo-controlled trials.18

This study aimed to analyse the distribution of change from baseline to week 24 in HbA1c and body weight in individual patients with type 2 diabetes (T2D) pooled from 5 of the core FORXIGA® (dapagliflozin) phase III, placebo-controlled clinical trials.

Patients with T2D received FORXIGA® (dapagliflozin) 10 mg/d (N=690) or placebo (N=689) for 24 weeks as:

  • Monotherapy (NCT00528372)
  • Add-on to metformin, ≥1500 mg/d (NCT00528879)  
  • Add-on to glimepiride, 4 mg/d (NCT00690745)   
  • Add-on to pioglitazone up to 45 mg/d (NCT00683878)*
  • Add-on to insulin, mean dose at baseline 77 IU/d (NCT00673231)

The primary efficacy end point was the change from baseline HbA1c after 24 weeks of treatment. The secondary endpoint was the change from baseline in body weight.

*The use of FORXIGA® (dapagliflozin) with pioglitazone is not recommended.1